GLOBUS MEDICAL INC - A (GMED)
US3795772082 - Common Stock
Taking everything into account, GMED scores 5 out of 10 in our fundamental rating. GMED was compared to 187 industry peers in the Health Care Equipment & Supplies industry. GMED has only an average score on both its financial health and profitability. GMED is growing strongly while it is still valued neutral. This is a good combination! This makes GMED very considerable for growth investing!
1. Profitability
1.1 Basic Checks
GMED had positive earnings in the past year.
In the past year GMED had a positive cash flow from operations.
In the past 5 years GMED has always been profitable.
GMED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
GMED has a Return On Assets of 1.80%. This is in the better half of the industry: GMED outperforms 73.26% of its industry peers.
The Return On Equity of GMED (2.25%) is better than 74.33% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.01%, GMED is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for GMED is in line with the industry average of 8.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.8% | ||
| ROE | 2.25% | ||
| ROIC | 3.01% |
ROA(3y)6.4%
ROA(5y)7.08%
ROE(3y)7.31%
ROE(5y)7.96%
ROIC(3y)6.95%
ROIC(5y)7.2%
1.3 Margins
Looking at the Profit Margin, with a value of 3.69%, GMED is in the better half of the industry, outperforming 74.33% of the companies in the same industry.
GMED's Profit Margin has declined in the last couple of years.
GMED has a better Operating Margin (6.80%) than 73.80% of its industry peers.
GMED's Operating Margin has declined in the last couple of years.
GMED has a Gross Margin of 58.14%. This is comparable to the rest of the industry: GMED outperforms 55.62% of its industry peers.
In the last couple of years the Gross Margin of GMED has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.8% | ||
| PM (TTM) | 3.69% | ||
| GM | 58.14% |
OM growth 3Y-4.18%
OM growth 5Y-12.3%
PM growth 3Y-15.46%
PM growth 5Y-18.62%
GM growth 3Y-3.53%
GM growth 5Y-3.48%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GMED is destroying value.
GMED has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GMED has more shares outstanding
The debt/assets ratio for GMED is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 9.01 indicates that GMED is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 9.01, GMED belongs to the best of the industry, outperforming 87.70% of the companies in the same industry.
GMED has a debt to FCF ratio of 1.49. This is a very positive value and a sign of high solvency as it would only need 1.49 years to pay back of all of its debts.
GMED's Debt to FCF ratio of 1.49 is amongst the best of the industry. GMED outperforms 88.77% of its industry peers.
GMED has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GMED (0.00) is better than 69.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.49 | ||
| Altman-Z | 9.01 |
ROIC/WACC0.33
WACC9.15%
2.3 Liquidity
A Current Ratio of 2.51 indicates that GMED has no problem at all paying its short term obligations.
GMED has a Current ratio of 2.51. This is comparable to the rest of the industry: GMED outperforms 44.92% of its industry peers.
A Quick Ratio of 1.64 indicates that GMED should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.64, GMED perfoms like the industry average, outperforming 43.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.64 |
3. Growth
3.1 Past
GMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
GMED shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.89% yearly.
The Revenue has grown by 102.10% in the past year. This is a very strong growth!
Measured over the past years, GMED shows a quite strong growth in Revenue. The Revenue has been growing by 17.08% on average per year.
EPS 1Y (TTM)25%
EPS 3Y17.67%
EPS 5Y6.89%
EPS Q2Q%45.61%
Revenue 1Y (TTM)102.1%
Revenue growth 3Y25.74%
Revenue growth 5Y17.08%
Sales Q2Q%63.1%
3.2 Future
The Earnings Per Share is expected to grow by 16.20% on average over the next years. This is quite good.
The Revenue is expected to grow by 16.13% on average over the next years. This is quite good.
EPS Next Y30.63%
EPS Next 2Y22.26%
EPS Next 3Y19.57%
EPS Next 5Y16.2%
Revenue Next Year60.09%
Revenue Next 2Y30.7%
Revenue Next 3Y22.22%
Revenue Next 5Y16.13%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
GMED is valuated quite expensively with a Price/Earnings ratio of 28.78.
Based on the Price/Earnings ratio, GMED is valued a bit cheaper than the industry average as 76.47% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of GMED to the average of the S&P500 Index (27.54), we can say GMED is valued inline with the index average.
With a Price/Forward Earnings ratio of 23.97, GMED is valued on the expensive side.
Based on the Price/Forward Earnings ratio, GMED is valued a bit cheaper than 78.07% of the companies in the same industry.
GMED is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.99, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.78 | ||
| Fwd PE | 23.97 |
4.2 Price Multiples
70.59% of the companies in the same industry are more expensive than GMED, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GMED indicates a somewhat cheap valuation: GMED is cheaper than 76.47% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 45.06 | ||
| EV/EBITDA | 30.34 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GMED's earnings are expected to grow with 19.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.94
PEG (5Y)4.18
EPS Next 2Y22.26%
EPS Next 3Y19.57%
5. Dividend
5.1 Amount
No dividends for GMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GLOBUS MEDICAL INC - A
NYSE:GMED (12/24/2024, 8:17:16 PM)
After market: 83.8232 +0.35 (+0.42%)83.47
+0.37 (+0.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners103.58%
Inst Owner Change-3.73%
Ins Owners0.78%
Ins Owner Change1.96%
Market Cap13.24B
Analysts77.27
Price Target92.35 (10.64%)
Short Float %1.81%
Short Ratio2.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.02%
Min EPS beat(2)8.6%
Max EPS beat(2)25.45%
EPS beat(4)3
Avg EPS beat(4)13.71%
Min EPS beat(4)-3.57%
Max EPS beat(4)25.45%
EPS beat(8)6
Avg EPS beat(8)7.77%
EPS beat(12)8
Avg EPS beat(12)4.08%
EPS beat(16)12
Avg EPS beat(16)7.74%
Revenue beat(2)2
Avg Revenue beat(2)0.95%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.57%
Revenue beat(4)3
Avg Revenue beat(4)0.65%
Min Revenue beat(4)-0.59%
Max Revenue beat(4)1.57%
Revenue beat(8)5
Avg Revenue beat(8)-0.45%
Revenue beat(12)6
Avg Revenue beat(12)-0.7%
Revenue beat(16)8
Avg Revenue beat(16)0.66%
PT rev (1m)13.83%
PT rev (3m)14.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.45%
EPS NY rev (1m)2.3%
EPS NY rev (3m)4.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.78 | ||
| Fwd PE | 23.97 | ||
| P/S | 5.34 | ||
| P/FCF | 45.06 | ||
| P/OCF | 31.9 | ||
| P/B | 3.25 | ||
| P/tB | 7.38 | ||
| EV/EBITDA | 30.34 |
EPS(TTM)2.9
EY3.47%
EPS(NY)3.48
Fwd EY4.17%
FCF(TTM)1.85
FCFY2.22%
OCF(TTM)2.62
OCFY3.13%
SpS15.63
BVpS25.66
TBVpS11.32
PEG (NY)0.94
PEG (5Y)4.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.8% | ||
| ROE | 2.25% | ||
| ROCE | 3.95% | ||
| ROIC | 3.01% | ||
| ROICexc | 3.6% | ||
| ROICexgc | 9.9% | ||
| OM | 6.8% | ||
| PM (TTM) | 3.69% | ||
| GM | 58.14% | ||
| FCFM | 11.85% |
ROA(3y)6.4%
ROA(5y)7.08%
ROE(3y)7.31%
ROE(5y)7.96%
ROIC(3y)6.95%
ROIC(5y)7.2%
ROICexc(3y)8.92%
ROICexc(5y)9.34%
ROICexgc(3y)12.19%
ROICexgc(5y)12.29%
ROCE(3y)9.12%
ROCE(5y)9.44%
ROICexcg growth 3Y-5.08%
ROICexcg growth 5Y-16.3%
ROICexc growth 3Y-22.02%
ROICexc growth 5Y-25.06%
OM growth 3Y-4.18%
OM growth 5Y-12.3%
PM growth 3Y-15.46%
PM growth 5Y-18.62%
GM growth 3Y-3.53%
GM growth 5Y-3.48%
F-Score6
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.49 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 47.17% | ||
| Cap/Sales | 4.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.53% | ||
| Profit Quality | 321.05% | ||
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.64 | ||
| Altman-Z | 9.01 |
F-Score6
WACC9.15%
ROIC/WACC0.33
Cap/Depr(3y)81.28%
Cap/Depr(5y)95.89%
Cap/Sales(3y)6.05%
Cap/Sales(5y)7.05%
Profit Quality(3y)112.15%
Profit Quality(5y)106.75%
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y17.67%
EPS 5Y6.89%
EPS Q2Q%45.61%
EPS Next Y30.63%
EPS Next 2Y22.26%
EPS Next 3Y19.57%
EPS Next 5Y16.2%
Revenue 1Y (TTM)102.1%
Revenue growth 3Y25.74%
Revenue growth 5Y17.08%
Sales Q2Q%63.1%
Revenue Next Year60.09%
Revenue Next 2Y30.7%
Revenue Next 3Y22.22%
Revenue Next 5Y16.13%
EBIT growth 1Y-29.07%
EBIT growth 3Y20.49%
EBIT growth 5Y2.67%
EBIT Next Year156.7%
EBIT Next 3Y48.9%
EBIT Next 5Y30.83%
FCF growth 1Y148.78%
FCF growth 3Y6.94%
FCF growth 5Y6.27%
OCF growth 1Y117.5%
OCF growth 3Y6.99%
OCF growth 5Y6.04%